Polarean Imaging – “Chest coil passes Philips compatibility testing”, but how significant for stock market investors?

Polarean Imaging (POLX) has announced that “its FDA-cleared… Chest Coil has successfully completed compatibility testing conducted by Philips and is now confirmed for use with Philips’ latest 3T MRI platforms… positions the technology for rapid clinical adoption and revenue generation”. What about this from a currently up to 0.1265p share price, though comparing to above 1.4p as recently as June?

Polarean Imaging – hopefully my prior warnings were heeded as it’s now set to seek shareholder approval to cancel stock market listing

On Polarean Imaging (POLX) announcing last month a “strategic review”, even with the shares further slumping to 0.25p I concluded to still avoid/sell. What about now an update from the company on that review and the shares currently further lower at 0.125p?

Polarean Imaging (#POLX) – intends to seek shareholder approval for AIM cancellation

Polarean Imaging – “strategic review” including potential AIM cancellation, but is it really all the fault of “the UK public market environment”?

Describing itself as “a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI”, Polarean Imaging (POLX) has issued an announcement commencing with that “its board of directors is undertaking a strategic review of the company’s future direction and organisational structure”. A “strategic review” though usually means that presently things are going wrong and it is currently not known how to solve them. So how much currently really is the company ‘a commercial-stage global leader’?

Polarean Imaging (#POLX) – “strategic review and consideration of AIM listing” (cancellation)

Polarean Imaging (#POLX) – trade-in agreement for two new “clinical-grade hyperpolariser systems”

Polarean Imaging – “delighted to announce today's successful placing and subscription”. Er, what about the more than 70% discount?!

Previously writing on Polarean Imaging (POLX), in September with the shares down to 11.5p and it emphasising it having “successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States”, I warned it’s the balance sheet which soon needed to be revolutionised and, considering the funding environment and a down to below £25 million market cap, it was good luck with such fundraising! Natch, avoid/sell. The shares most recently closed at 3.7p and now CEO Christopher von Jako is “delighted to announce today's successful placing and subscription of $10 million”. Er, why are the shares currently at 1.3p then, a further 65% down?!

Polarean Imaging (#POLX) – bailout $10m (£8m) placing at just 1p per share

Polarean Imaging – interims talk of ‘revolutionising’ medicine but it’s the balance sheet which soon needs to be revolutionised!

Previously writing on Polarean Imaging (POLX), a medical imaging company which emphasises it has “developed the first and only hyperpolarised MRI contrast agent to be approved in the United States”, in February with the shares falling below 40p I concluded that the valuation and financial outlook in a still-challenging funding environment meant I certainly avoided. The shares most recently closed at 14.5p, and what of they currently at 11.5p on the back of half-year results?

Polarean Imaging (#POLX) – can now access its Silicon Valley Bank accounts, shares to resume trading on AIM

Polarean Imaging – has “cash, which is expected to fund the company until May 2024”… or not?!

Medical imaging technology company Polarean Imaging (POLX) has issued a “Company Update” announcement including that it “finished 2022 with approximately $16M in cash, which is expected to fund the company until May 2024” and that it is now looking “to demonstrate the establishment of commercial traction and clinical adoption beyond our existing global research base”. Sounds ok, so what of a current share price response down by more than 12% to below 40p?

Polarean Imaging (#POLX) – FDA approval for drug device combination product XENOVIEW for evaluation of lung ventilation

Polarean Imaging (#POLX) – U.S. FDA 'additional information request', company notes assurances drug manufacturing partner will address concerns

Polarean Imaging (#POLX) – raises full £2m proposed under open offer

Polarean Imaging (#POLX) – £3.125m fundraising at 14p per share, a 15% discount